Blood Preparation Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Blood Preparation Market Trends and Insights

Increasing Global Surgical Procedures Volume

Elective and trauma-related surgeries are rebounding in 2025, boosting demand for red-cell concentrates and plasma components. Hospitals in the United States increased orthopedic procedure counts by 8% year-on-year, prompting upgrades in component storage and rapid-type testing. Similar momentum is visible in Western Europe, where minimally invasive techniques encourage outpatient surgeries that still require pre-operative blood matching. Automated cross-matching analyzers and digital blood-bank software shorten turnaround times, improving utilization rates for every donated unit. These developments strengthen revenue visibility for the blood preparation market.

Growing Prevalence of Chronic and Hematologic Disorders

Chronic kidney disease, hematologic cancers, and hemophilia continue to rise across Asia-Pacific, expanding recurring demand for plasma-derived immunoglobulins and coagulation factors^{[1]World Health Organization, “Global Status Report on Blood Safety and Availability 2024,” WHO, who.int}. Government reimbursement lists in China and India now include subcutaneous immunoglobulin therapy, accelerating patient access. Multinationals respond by adding fractionation lines and donor centers, while domestic firms partner for technology transfer. The broad disease burden ensures long-term pull for blood derivatives, reinforcing sustainable growth for the blood preparation market.

Rising Government Support for Blood Collection Infrastructure

Indonesia’s first plasma-fractionation plant, designed for 600,000 liters annual capacity by 2026, demonstrates how emerging economies prioritize domestic self-sufficiency. The European Union’s Substances of Human Origin Regulation (2024/1938) mandates harmonized collection standards and projects the need for 2 million new voluntary donors^{[2]European Parliament, “Regulation (EU) 2024/1938 on Substances of Human Origin,” europarl.europa.eu}. National grants in Japan and South Korea subsidize apheresis equipment, widening the donor pool and modernizing collection practices. Such fiscal incentives underpin infrastructure modernization, enlarging the blood preparation market.

Advancements in Blood Screening and Processing Technologies

Terumo Blood and Cell Technologies’ Reveos system slashes manual steps from 26 to 9 and processes four whole-blood units simultaneously, lifting component yield per donation. Cerus Corporation’s INTERCEPT platform achieved 20% revenue growth in 2024 as Canadian Blood Services adopted 100% pathogen-reduction processing. Robotic phlebotomy pilots in Europe reach a 95% first-stick success rate, alleviating staffing constraints and improving donor experience. Collectively these innovations bolster productivity and safety, broadening the clinical appeal of the blood preparation market.

Risk of Transfusion-Transmitted Infections

Studies in Uganda reported 13.8% prevalence of transfusion-transmitted infections among donors, with HBV and HCV notably high. While pathogen-reduction systems cut malaria transmission risk by 87%, budget limitations hinder adoption where the threat is greatest. International-donor agencies fund pilot programs, yet scalability lags behind infection growth. The persistent gap emphasizes the need for affordable sterilization, tempering absolute growth of the blood preparation market.

High Cost of Advanced Blood Preparation Technologies

Fully automated fractionation lines require multi-million-dollar capital outlays, and lab-grown blood currently costs USD 2,000 per unit. Smaller blood centers struggle to justify upgrades despite long-term efficiency gains. In developing markets, tariff barriers on imported disposables inflate operating expenses. Public–private partnerships and tiered-pricing models are emerging to bridge affordability, but until pricing falls further, cost pressures restrict wider roll-out of next-generation tools within the blood preparation market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Blood Derivatives Lead Despite Component Innovation

Blood derivatives held 47.98% of 2025 revenue, anchored by strong immunoglobulin and coagulation factor demand. The pulmonary embolism segment accounted for 27.31% share of the blood preparation market size in 2025, supporting derivative consumption in acute settings. CSL Behring logged 20% sales growth for immunoglobulins, aided by a 22% drop in plasma collection cost per liter, illustrating scale economics that favor large fractionators. Automated systems such as Reveos drive 8.12% CAGR for blood components, delivering higher platelet and red-cell yields per unit, lowering wastage, and extending storage times from 42 to 63 days through super-cooling preservation. Increasing hospital adoption of component-specific transfusion protocols sustains this expansion for the blood preparation market.

The derivatives pipeline remains buoyant. Grifols projects USD 1 billion cumulative sales for Yimmugo over seven years post-FDA approval. European governments aim to reach 80% self-sufficiency in albumin by 2030, stimulating domestic contract fractionation programs. Parallel advances in whole-blood robotics and artificial substitutes offer long-range alternatives but will take time to displace established derivatives. Consequently, derivatives retain leadership even as component innovation elevates the efficiency and profitability of the blood preparation market.

By Blood Thinning Agents: Anticoagulant Dominance Faces Innovation Pressure

Anticoagulants represented 60.88% of 2025 revenue, reflecting entrenched clinical guidelines and physician familiarity. Abelacimab, a factor XI inhibitor, reduced bleeding by 67% versus rivaroxaban in atrial-fibrillation trials, propelling platelet-aggregation inhibitor growth at an 8.29% CAGR. Apixaban remained Australia’s most prescribed oral anticoagulant, costing the health system USD 500 million in 2024. The pulmonary embolism segment captured 27.31% share of the blood preparation market, reinforcing anticoagulant volumes across emergency and chronic settings.

Four-factor prothrombin complex concentrate is displacing frozen plasma during cardiac surgery, lowering major bleeding by nearly 50%. Fibrinolytics hold steady demand but face increasing competition from recombinant hemostatic drugs that shorten infusion times. As factor XI agents enter late-stage development, prescribing patterns may pivot, but established anticoagulants will continue to anchor revenue for the blood preparation market during the forecast horizon.

By Application: Pulmonary Embolism Leadership Challenged by Renal Growth

Pulmonary embolism held 27.31% revenue share in 2025, supported by upgraded imaging and risk-stratification tools that encourage earlier intervention. Within this cohort, factor XI inhibitors are expected to capture share because they minimize bleeding risks in high-thrombotic states. Renal impairment therapies expand at 8.74% CAGR, reflecting the growing chronic-kidney-disease patient base in Asia-Pacific and the need for specialized anticoagulation protocols. Precision dosing algorithms based on glomerular-filtration rates are improving safety and reducing readmissions, enhancing adoption across nephrology clinics.

Thrombocytosis management leverages novel aggregation inhibitors, and cancer-associated thrombosis drives additional uptake of low-molecular-weight heparins. Pediatric anticoagulation remains niche but is poised for growth as safety data become more robust. These shifts illustrate how tailored therapies sustain demand diversification within the blood preparation market.

By End User: Hospital Dominance Shifts Toward Specialized Centers

Hospitals and surgical centers secured 45.22% of 2025 revenue, benefiting from integrated blood-management programs that reduced wastage by 12% at leading U.S. academic centers. Nonetheless blood and plasma banks will grow 9.11% CAGR as apheresis automation enables higher throughput without extra donations, enhancing cost efficiency for regional blood systems. Sanquin’s national roll-out of Reveos added capacity equivalent to 90,000 additional platelet pools annually without additional donors.

Ambulatory surgery centers deploy point-of-care hemoglobin testing that shortens pre-op screening to five minutes, supporting decentralized care. Home-health providers increasingly use capillary collection devices that deliver venous-quality samples, broadening access for chronic-disease monitoring. The changing end-user mix highlights the flexibility and reach of the blood preparation market.

Geography Analysis

North America retained 38.12% of 2025 revenue, underpinned by 350 CSL Plasma donor centers and rapid uptake of the Rika collection system, which cuts donation time by 15 minutes. The region’s elaborate regulatory agenda, with five blood-focused guidance documents slated for 2025, accelerates technology approval and adoption. Yet climate disruptions dent supply: the American Red Cross saw a 25% inventory drop in July 2024 during extreme heat and storms.

Asia-Pacific registers the highest 7.14% CAGR. Terumo’s USD 15 million Hangzhou plant enhances local production, while Indonesia’s plasma-fractionation project fast-tracks regional self-sufficiency. Japan’s artificial-blood program at Nara Medical University could revolutionize emergency transfusion with two-year shelf life and universal compatibility. Europe focuses on autonomy under the new SoHO regulation, requiring 2 million extra donors and common quality standards across member states. The United Kingdom is on track for 25% immunoglobulin self-sufficiency by 2025, aided by domestic fractionation contracts gov.uk. Sanquin’s adoption of automated processing in the Netherlands demonstrates how technology reduces dependence on incremental donations. These geographic dynamics collectively reinforce a balanced global outlook for the blood preparation market.

Regulatory Landscape

Blood preparation is regulated as a biologics and blood establishment activity, with manufacturing and quality controls anchored by FDA CBER requirements in the United States. Production of blood and blood components is governed by current good manufacturing practice under 21 CFR Part 606, and facilities must register under 21 CFR Part 607; Biologics License Applications (BLAs) are required for licensed products and certain manufacturing changes. In May 2026, the FDA held a public webinar on BLA review for blood and source plasma, reinforcing ongoing scrutiny of donor suitability, testing, and manufacturing controls as the market adopts higher-throughput automation and pathogen-reduction workflows.

In Europe, oversight is shifting from the legacy Directives 2002/98/EC and 2004/23/EC toward the Substances of Human Origin framework via Regulation (EU) 2024/1938 (SoHO Regulation), which is scheduled to apply from August 7, 2027 and increases emphasis on harmonized donor eligibility, testing, and traceability. The European Medicines Agency continues to use Plasma Master File (PMF) certification as a core mechanism to demonstrate plasma quality, and it is revising PMF scientific data requirements during the 2024-2026 workplan to align expectations with the new SoHO rules. Across trade flows, blood fractions and immunological products commonly move under HS codes such as 3002.12.00 and 3002.49.00, supporting cross-border sourcing of plasma-derived products where domestic collection is constrained.

Value Chain Analysis

The value chain starts with donor recruitment and collection (whole blood and plasmapheresis) managed by public/non-profit blood establishments and private-for-profit plasma center networks. It then moves through testing, component separation, and cold-chain storage for distribution to hospitals and surgical centers. For blood derivatives, the chain extends into fractionation and fill-finish of plasma-derived medicinal products (PDMPs), where long production cycles and stringent quality systems make plasma the finite, rate-limiting input; this structure supports vertical integration among large multinationals that control collection through distribution. Downstream, group purchasing and hospital blood-management programs shape the product mix (components versus derivatives) and increase demand for standardized processing, including automation and pathogen reduction, to reduce wastage and improve utilization.

Key constraints concentrate around plasma collection and resilience. Europe remains structurally reliant on imports, and supply tightness has surfaced in products such as anti-D immunoglobulin; in July 2025, the European Medicines Agency issued recommendations to member states to strengthen anti-D immunoglobulin supply, including national planning and therapeutic alternatives, highlighting how donor availability and limited local manufacturing capacity can ripple through the entire chain. Policy initiatives and coordination bodies (EDQM, WHO guidance on cross-border plasma transfers, and EU workstreams such as the Critical Medicines Act discussions) are pushing toward better data interoperability, risk-based oversight, and contract/toll fractionation models that let public collectors retain control of domestic plasma while leveraging industrial fractionation capacity.

Market Opportunities and Future Outlook

A major opportunity is in industrializing and standardizing processing at blood centers and hospital-adjacent labs through automated, closed, and higher-yield workflows that reduce manual steps and variability in component preparation. In March 2026, Hemanext received FDA 510(k) clearance for expanded indications for its Hemanext ONE system to process leukocyte-reduced red blood cells from whole blood-derived or apheresis-derived inputs (CP2D/AS-3), supporting adoption of integrated processing platforms that align with cGMP-driven documentation and consistency needs.

Decentralized and modular production models also create whitespace, particularly for emergency readiness and remote settings where conventional frozen plasma logistics are difficult. Velico Medical reported that France's Armed Forces Blood Transfusion Centre (CTSA) received the first containerised spray-dried plasma manufacturing system (veliPod) in February 2026, indicating procurement interest in deployable capability that can supplement traditional blood bank supply chains. In parallel, the EU transition to Regulation (EU) 2024/1938 (SoHO) and the EMA work to revise Plasma Master File requirements are driving operational upgrades in traceability, donor eligibility documentation, and plasma quality dossiers, creating near-term demand for compliant data systems and standardized plasma governance across collection, fractionation, and distribution.